🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Kyowa Kirin Co Ltd (4151)

Tokyo
Currency in JPY
2,626.0
+11.5(+0.44%)
Closed
4151 Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
2,594.52,631.5
52 wk Range
2,266.53,350.0
Bid/Ask
2,620.50 / 2,621.00
Prev. Close
2,614.5
Open
2,598
Day's Range
2,594.5-2,631.5
52 wk Range
2,266.5-3,350
Volume
524,200
Average Vol. (3m)
1,667,746
1-Year Change
7.12%
Fair Value
Unlock
Fair Value Upside
Unlock
4151 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
3,307.7
Upside
+26.2%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Kyowa Kirin Co Ltd Company Profile

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Employees
5982
Market
Japan

Compare 4151 to Peers and Sector

Metrics to compare
4151
Peers
Sector
Relationship
P/E Ratio
16.0x13.9x−0.6x
PEG Ratio
0.360.010.00
Price / Book
1.6x1.1x2.6x
Price / LTM Sales
2.7x1.7x3.2x
Upside (Analyst Target)
33.9%12.0%43.4%
Fair Value Upside
Unlock13.0%6.4%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 156.74
Dividend Yield
2.22%
Industry Median 2.25%
Annualized Payout
58
Paid unevenly
5-Years Growth
-
Growth Streak

People Also Watch

4,683.0
4307
-1.10%
2,592.0
6479
-0.42%
2,439.5
2432
+15.97%
3,366.0
5214
-0.91%
1,216.0
8233
-1.78%

FAQ

What Is the Kyowa Kirin (4151) Stock Price Today?

The Kyowa Kirin stock price today is 2,626.00

What Stock Exchange Does Kyowa Kirin Trade On?

Kyowa Kirin is listed and trades on the Tokyo stock exchange.

What Is the Stock Symbol for Kyowa Kirin?

The stock symbol for Kyowa Kirin is "4151."

Does Kyowa Kirin Pay Dividends? What’s The Current Dividend Yield?

The dividend yield is 2.22%.

What Is the Kyowa Kirin Market Cap?

As of today, Kyowa Kirin market cap is 1.33T.

What is Kyowa Kirin Earnings Per Share?

The Kyowa Kirin EPS is 156.74.

What Is the Next Kyowa Kirin Earnings Date?

Kyowa Kirin will release its next earnings report on Feb 06, 2025.

From a Technical Analysis Perspective, Is 4151 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.